Skip to headerSkip to main contentSkip to footer
Get our Free E-newslettersGet our Free E-newsletters
Kiplinger logoLink to homepage
Get our Free E-newslettersGet our Free E-newsletters
Subscribe to Kiplinger
Subscribe to Kiplinger
Save up to 76%
Subscribe
Subscribe to Kiplinger
  • Store
  • Home
  • Investing
  • Retirement
  • Taxes
  • Personal Finance
  • Your Business
  • Wealth Creation
    • Podcasts
    • Economic Outlooks
    • Tools
    • Kiplinger's Personal Finance Magazine
    • The Kiplinger Letter
    • The Kiplinger Tax Letter
    • Kiplinger's Investing for Income
    • Kiplinger's Retirement Report
    • Store
    • Manage My E-Newsletters
    • My Subscriptions
Skip advert
  • Home
  • investing
  • stocks
  • stocks to buy
stocks to buy

5 Stock Picks With Bulletproof Profit Margins

Companies that can squeeze a lot of blood from the revenue stone can flourish, even in tough times.

by: Nellie S. Huang
April 27, 2022
A businessman opening up his jacket to reveal a bulletproof superhuman body suit

Getty Images

Skip advert

Making good stock picks is challenging at any time. But these days, investors must be wary of companies that are vulnerable to higher-for-longer inflation, as well as lingering supply-chain disruptions, rising interest rates and the scary geopolitical situation in eastern Europe. 

Some companies hold up better than others in tough times. Firms that lead their market or industry, for example, typically have strong pricing power – think Apple or Nike. These types of companies can pass on higher wages and material costs to customers by raising prices for goods or services without seeing much slip in demand.

  • The 15 Best Stocks to Buy for the Rest of 2022

Other firms fortify their results by controlling costs (Johnson & Johnson has proved adept at this in years past). Still others have businesses that are simply less sensitive to rising material and labor costs, or even supply-chain issues, because of the services or goods they sell (Netflix, say, or Airbnb). 

One way to find companies with those attributes is to scrutinize profit margins. Why not profits alone? A company's bottom line – its net income or profit – matters, of course. But profit margins can show how efficiently a company manages its operations and costs over time, in good and bad periods. Well-managed firms can maintain or expand profit margins through changing economic and market conditions. Often, these companies also have strong balance sheets and a steady stream of free cash flow (cash profits left after expenses to maintain or expand the business).

"These companies are well placed to do well in different economic environments," says Ian Mortimer, portfolio manager of SmartETFs Dividend Builder ETF (DIVS).  

There are different ways to measure profit margins. Gross margins show the percentage of revenue that remains after deducting the costs of producing the goods or services a company has sold. Operating margins reflect the percentage of revenue left after on-going expenses to run the business, which includes the costs of goods, wages and other expenses related to running the company. And net margins are the ratio of net income to revenues and show how much of every dollar actually hits the bottom line.  

The stock picks below have the potential for improving profit margins of one kind or another. In most cases, we're talking about gross margins, but in a few cases, we refer to operating or net margins. We also looked for growth catalysts that might propel profits higher, as well as reasonably valued shares relative to peers or the broad market.

  • The 15 Best Value Stocks to Buy Right Now

Returns and data are through April 26.

Skip advert
Skip advert
Skip advert

1 of 5

Amazon.com

An Amazon delivery box

Getty Images

Skip advert
  • Market value: $1.4 trillion

E-commerce giant Amazon.com (AMZN, $2,814.50) just raised its annual membership fee for Prime (its free shipping and streaming video services) by 17%, to $139 from $119. It's a good bet that most of Prime's current 200 million members, and perhaps millions more, will pony it up. The last time Amazon increased the annual fee (in 2018 by 20%), the number of subscribers doubled in three years. That's pricing power.

More important, however, is the shift in Amazon's overall business to a mix with higher gross margins.

E-commerce is still the main business, and online retail is a low-margin trade. However, Amazon's growth now comes from two other businesses with healthy margins: advertising sales and Amazon Web Services, its cloud-computing business.

And they're growing fast. Ad sales – for spots on Amazon's website, Prime Video and Fire TV – topped $31 billion in 2021, a 58% jump from 2020. The firm's new contract to stream the NFL's Thursday Night Football games should propel ad sales even more this year. And AWS revenues, which account for 13% of overall sales, increased 37% in 2021.

As these divisions continue to grow, it should fatten Amazon's gross margins to 43.5% in 2023, up from 42.0% in 2021, says analyst CFRA analyst Tuna Amobi. Look past 2022, during which wage inflation and investments in shipping and logistics may hamper gross-margin expansion.

Amazon's not exactly among the cheapest stock picks you'll find right now – shares trade at a whopping 53 times estimated earnings for the year ahead. But that's a discount to its five-year historical P/E of 85. And analysts expect the mega-cap company to pump out 25% average annual earnings growth over the next three years. 

  • 12 Good Reasons to Cancel Amazon Prime
Skip advert
Skip advert
Skip advert

2 of 5

Bio-Techne

Bio-Techne building in St. Paul, Minnesota

Getty Images

Skip advert
  • Market value: $15.0 billion

The pandemic revitalized spending on health-science research, and that's to the benefit of Bio-Techne (TECH, $382.54). The company is a leader in the production of proteins, antibodies and other compounds used in medical research, drug development and diagnostic tests. Its proteins, for instance, are necessary for COVID vaccines and treatments. 

Sign up for Kiplinger's FREE Closing Bell e-letter: Our daily look at the stock market's most important headlines, and what moves investors should make.

That's just part of the reason Argus Research analyst David Toung rates Bio-Techne stock a Buy.

The company is re-investing its robust operating cash flow to expand production capacity and make what Toung calls tuck-in acquisitions – small cash deals for private companies. It has completed more than a dozen such deals since 2014. Most recently, in 2021 it acquired Asuragen, a maker of diagnostic and research products such as oncology testing kits, for $215 million in cash plus $105 million more if certain milestones are achieved.

Andy Adams, a portfolio manager with the mutual fund company Mairs & Power, says the company has been able to improve gross margins in recent years, from 65% in 2017 to 68.1% in 2021, despite its many acquisitions.  

Analysts predict average annual earnings growth of 26% over the next three years. That comes at a premium, however, and shares trade at a price-earnings multiple of 45 times year-ahead estimates. Still, that's below the average P/E for biotech firms of 59. 

  • The 12 Best Healthcare Stocks to Buy for the Rest of 2022
Skip advert
Skip advert
Skip advert

3 of 5

Broadcom

A Broadcom semiconductor

Getty Images

Skip advert
  • Market value: $228.7 billion

Semiconductor giant Broadcom (AVGO, $555.05) is best known for its networking-switch chips for data centers and its radio-frequency filters for high-end smartphones. But thanks to well-executed acquisitions, Broadcom is highly diversified across a range of fast-growing tech areas.

"Put it all together, and you have a combination of end markets with big growth," from cloud computing and factory automation to data centers and 5G, says Mortimer, the Dividend Builder portfolio manager. "That will drive growth regardless of the economic environment." 

The company is extremely profitable and well run. Annual gross margins have climbed steadily in recent years. And analysts expect them to widen to 76% over the next two fiscal years (ending in October), up from 73.9% in fiscal 2021. Meanwhile, costs have barely budged in recent years, and the company pays a hefty dividend, which it has raised for 13 consecutive years. 

The semiconductor industry has been dealing with supply-chain bottlenecks since the start of the pandemic, says John Buckingham, editor of investing newsletter The Prudent Speculator. Broadcom isn't immune to that, but its size and "tight" supplier relationships have helped minimize the impact, he says. AVGO has a good handle on supply and demand through the first half of 2023, and so far, it has been passing on material cost increases to customers. 

Analysts expect earnings to jump an average of 15% a year over the next three years. And shares trade at 17 times expected year-ahead earnings, below the typical P/E of 21 for its semiconductor peers. 

  • The 12 Best Tech Stocks to Buy for 2022
Skip advert
Skip advert
Skip advert

4 of 5

Moderna

Several rows of Moderna COVID vaccines

Getty Images

Skip advert
  • Market value: $58.8 billion

Moderna (MRNA, $144.14) doesn't fit squarely in the expanding-profit-margin box, at least historically.

The biotech stock, a pioneer in mRNA technology, has only just become profitable thanks to demand last year for its COVID-19 vaccine. In 2021, Moderna reported $28.29 in earnings per share, a titanic shift from its $2 loss per share the previous year. Gross margins were a fat 75.1% for 2021, above the 61.3% average for peers, and a net profit margin of 66.0% was well ahead of the average 19% for the biotech industry, according to Zacks Investment Research. 

Shares are down 70% from their high last August – a much bigger decline than the typical biotech stock experienced – which makes Moderna a compelling value. The stock suffered as investors worried that its COVID vaccine was less effective against new variants of the virus. 

But Moderna has plenty of irons in the fire. It is still working on new coronavirus treatments, including vaccines for specific variants. It has signed $19 billion in agreements for its COVID vaccine for this year, and it has $3 billion more in potential orders for the vaccine in 2023. Plus, Moderna has 44 vaccines and therapeutics in development, half of which are in later-stage clinical trials, including mRNA-based vaccines for the flu and Zika and a personalized cancer vaccine. 

What's more, the company is a financial stronghold, with $17.6 billion in cash and investments and minimal debt. Analysts expect 2022 earnings to be a tad lower than in 2021, but they see growth of 7% per year, on average, over the next three years. At current prices, Moderna trades at a price-earnings multiple of 5.3, a fraction of the average P/E of 59 for biotech stocks. 

  • The 15 Best Growth Stocks to Buy for the Rest of 2022
Skip advert
Skip advert
Skip advert

5 of 5

Visa

Visa cards in a wallet

Getty Images

Skip advert
  • Market value: $421.9 billion

Visa (V, $209.36) payment-processing network operates like a toll booth, so the more electronic transactions that Visa handles, the higher the company's revenue.

Sign up for Kiplinger's FREE Investing Weekly e-letter for stock, ETF and mutual fund recommendations, and other investing advice.

The ongoing shift to digital payments and online shopping has been a boon, as has strong growth in transactions using the company's crypto-linked cards, which make it easy to pay for products and services with digital currencies. A sharp recovery in international travel and cross-border money flows offers more upside. As long as higher price tags don't crimp consumer spending, stickier inflation is a positive: About 55% to 60% of Visa revenues will get a boost from inflation, says CFRA analyst David Holt.

Holt pays close attention to Visa's operating expenses and margins. If the firm can control costs, any increase in revenue from higher transaction volumes falls to its bottom line.

"The beauty of Visa's business model is its operating leverage. As volume builds, operating margins expand," says Holt, who rates the stock a "buy." 

He sees operating margins widening over the next two years to 68.0% by the end of 2023, up from 65.6% in 2021, helping to fuel roughly 20% earnings growth over that period. He thinks the shares deserve a P/E of 38, which, applied to per share earnings estimates of more than $7 for the fiscal year ending in September, results in his 12-month price target of $270.

That's an "above-market P/E multiple," Holt says, but it's supported by achievable revenue targets and well-controlled expenses.

  • The 12 Best Financial Stocks to Buy for 2022
Skip advert
Skip advert
Skip advert
  • stocks to buy
  • Amazon.com (AMZN)
  • Broadcom (AVGO)
  • Moderna (MRNA)
  • Visa (V)
Share via EmailShare on FacebookShare on TwitterShare on LinkedIn
Skip advert
Skip advert
Skip advert
Skip advert

Recommended

Hydrogen Stocks: Unstable, But Potentially Explosive, Too
ESG

Hydrogen Stocks: Unstable, But Potentially Explosive, Too

Green hydrogen is in its relative infancy, making related stocks quite volatile. But long-term investors can use that to their advantage.
June 30, 2022
5 Best Dow Dividend Stocks to Buy Now
blue chip stocks

5 Best Dow Dividend Stocks to Buy Now

This mini-portfolio of blue-chip dividend payers is well-positioned to both generate income and hold up to headwinds for the rest of 2022.
June 27, 2022
The 15 Best Stocks for the Rest of 2022
stocks to buy

The 15 Best Stocks for the Rest of 2022

The lesson of the past two years: Be ready for anything. Our 15 best stocks to buy for the rest of 2022 reflect several possible outcomes for the seco…
June 21, 2022
The Best Stocks for a Bear Market
stocks to buy

The Best Stocks for a Bear Market

The ideal bear-market stock pick should have a defensive business, a long history of dividend growth and relatively low volatility. Here are 10 stocks…
June 13, 2022

Most Popular

5 Ways to Prepare for a Recession
recession

5 Ways to Prepare for a Recession

The signs seem to be pointing in one direction these days, so if you’re worried about being ready for a recession, consider taking these five measures…
June 28, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
In What Order Should You Tap Your Retirement Funds?
retirement planning

In What Order Should You Tap Your Retirement Funds?

Should you go with your IRA first or your brokerage account? Pulling money haphazardly can have negative implications. Instead follow this road map fo…
June 28, 2022
  • Customer Service
  • About Us
  • Advertise With Us (PDF)
  • Privacy Policy
  • Cookie Policy
  • Kiplinger Careers
  • Accessibility
  • Privacy Preferences

Subscribe to Kiplinger's Personal Finance

Be a smarter, better informed investor.
Save up to 76%Subscribe to Kiplinger's Personal Finance
Do Not Sell My Information

Kiplinger is part of Future plc, an international media group and leading digital publisher. Visit our corporate site www.futureplc.com
© Future US LLC, 10th floor, 1100 13th Street NW, Washington, DC 20005. All rights reserved.

Follow us on InstagramFollow us on FacebookFollow us on TwitterConnect on LinkedInConnect on YouTube